A number of recent studies have reported the detection of the ubiquitous human polyomavirus, JC virus (JCV), in samples derived from several types of neural as well as non-neural human tumors. The human neurotropic JCV was first identified as the etiologic agent of the fatal demyelinating disease, progressive multifocal leukoencephalopathy, which usually occurs in individuals with defects in cell-mediated immunity, including AIDS. However, upon mounting evidence of the oncogenic potential of the viral regulatory protein, T-antigen, and JCV's oncogenecity in a broad range of animal models, studies were initiated to determine its potential involvement in human carcinogenesis. Initially, the most frequently observed tumors in rodent models, including medulloblastoma, astrocytoma, glioblastoma, and other neural-origin tumors were analysed. These studies were followed by analysis of non-neural tumors such as colorectal carcinomas. In a subset of each tumor type examined, JC viral genomic DNA sequences could be detected by PCR and confirmed by Southern blot hybridization or direct sequencing. In a smaller subset of the tumors, the expression of T-antigen was observed by immunohistochemical analysis. Owing to the established functions of T-antigen including its ability to interact with tumor suppressor proteins such as Rb and p53, and its ability to influence chromosomal stability, potential mechanisms of JCV T-antigen-mediated cellular dysregulation are discussed. Further, as increasing evidence suggests that T-antigen is not required for maintenance of a transformed phenotype, a hit-and-run model for T-antigen-induced transformation is proposed.
Introduction
The human neurotropic JC virus (JCV) is a member of the polyomavirus family, which includes the human BK virus (BKV) and the simian virus 40 (SV40). Both JCV and BKV are thought to infect approximately 80% of the human population in early childhood and to establish latency in the kidney. Upon reactivation because of immunosuppression, JCV induces the once rare demyelinating disease progressive multifocal leukoencephalopathy (PML) most frequently seen in AIDS patients, while BKV induces polyomavirus nephropathy, an increasingly common side effect of immunosuppressive therapy in renal transplant recipients. While the question as to whether SV40 represents a human polyomavirus, or was introduced into humans through contaminated poliovaccine is still under debate, serologic evidence suggests that SV40 now circulates within the human population. Although a potential site of latency for SV40 has not been established, a number of studies have reported the detection of the virus in human tumors including mesotheliomas and osteosarcomas, as well as two rare CNS tumors, ependymomas and choroid plexus papillomas (reviewed in Arrington and Butel, 2001 ). In addition, there have been several reports of BKV DNA detected in normal tissues and cell lines including the urogenital tract, brain, bone, peripheral blood cells, as well as one report in which BKV RNA was detected in bone, brain, and peripheral blood cells by Northern blot or RT-PCR raising the question as to whether polyomaviruses may be present in normal tissues or peripheral blood (reviewed in De Mattei et al., 1995; Corallini et al., 2001) . In this review, we will consider the literature concerning the oncogenic potential of JCV in experimental animal models and summarize what has been reported regarding the association of JCV with human neoplasias. These observations, coupled with in vitro experiments aimed at understanding the molecular pathways affected by viral gene expression, will help elucidate potential mechanisms of tumorigenesis by JCV.
Progressive multifocal leukoencephalopathy
First described in 1958, PML was once considered a rare disorder, which occurred in individuals with immunosuppressive disorders such as Wiscott Aldridge syndrome, individuals receiving chemotherapy, or infrequently in elderly individuals (Walker and Padgett, 1983; Price, 1996) . Since the AIDS epidemic, however, PML has become an increasingly common neurological complication in the developed world in that up to 10% of HIV-1-positive individuals are predicted to become symptomatic during the course of their antiretroviral therapy (Berger and Concha, 1995) . Individuals suffering from PML usually present with decreased motor coordination or cognitive impairment and contrastenhancing lesions may be observed in the white matter of the cortex upon magnetic resonance imaging. These lesions represent areas of viral replication within oligodendrocytes, the myelin-producing cells of the CNS. During the process of active viral infection, the host oligodendrocytes succumb to lytic destruction. Treatment strategies for PML have aimed at controlling viral replication, but are currently at an experimental stage and the prognosis remains poor for the majority of affected individuals.
Microscopically, the white matter lesions appear as areas of demyelination when sections of formalin-fixed paraffin-embedded tissue are stained with luxol fast blue and observed at low magnification ( Figure 1a ). Oligodendrocyte inclusion bodies, which contain enlarged glassy nuclei, are plentiful at the periphery of active lesions and represent cells in which viral replication is occurring (Figure 1c ). When the nuclear inclusion bodies are viewed by electron microscopy, dense sheets of 45 nm icosahedral capsids consistent with polyomaviridae size and structure can be seen (panel d). Interestingly, reactive or bizarre astrocytes are abundant, some of which may exhibit features observed in transformed cells such as multinucleation and pleomorphism ( Figure 1d ).
Viral early protein, T-antigen
The polyomaviruses share a similar structure with genomes composed of double-stranded circular DNA encoding the viral early proteins, T-and t-antigen, and the viral late genes encoding the capsid proteins VP1, VP2, and VP3 as well as the accessory Agno protein.
The early and late coding regions are separated by a bidirectional regulatory region, which is the most divergent region among the three viruses. The viral regulatory protein, T-antigen, plays a critical role in the viral lifeycle in that it directs viral early and late gene expression and viral DNA replication during lytic infection . In addition to its role in viral regulation during active replication, JCV T-antigen is considered an oncogene because of its demonstrated ability to transform cells in culture. Although JCV does not appear to have the same efficiency of transformation as the well-described SV40 T-antigen, cells expressing JCV T-antigen exhibit characteristics of transformed or immortalized cells including morphological changes such as multinucleation, rapid doubling time, growth in anchorage independence, and subcutaneous growth in the Nude mouse. JCV has successfully been used to transform rat fibroblasts and baby hamster kidney cells, albeit at low frequencies (Bollag et al., 1989; , 1989) . Indeed, JCV and SV40 T-antigens share approximately 70% sequence homology, with the C-terminal region that is responsible for host range and specificity being the most divergent. Similar to SV40, JCV T-antigen maintains helicase, a-polymerase, ATPase, and DNA-binding activities (Frisque et al., 1984) . In addition, JCV T-antigen has been shown by coimmunoprecipitation studies to interact physically with the tumor suppressor protein, p53 and the retinoblastoma protein family members, pRb, p130, and p107 (Bollag et al., 1989; Dyson et al., 1989 Dyson et al., , 1990 Ludlow and Skuse, 1995; Krynska et al., 2000) . It is through binding that T-antigen is thought to sequester and inactivate p53 and pRb, subsequently affecting normal cell-cycle regulatory controls. While SV40 Tantigen has shown its ability to immortalize a broad range of cells in vitro as well as to induce tumorigenesis in countless transgenic mouse lines, the transforming ability of JCV T-antigen had appeared to be limited to neural-origin tissue based on a number of observations in cell culture and animal models. However, more recent evidence has potentially expanded the range of cell types to those outside the CNS, as outlined below, and suggests more broad implications for the oncogenic potential of JCV T-antigen.
Transmission, latency, and cellular tropism JCV is considered a ubiquitous virus that is believed to infect individuals early in life and establish a subacute chronic infection in the kidney. In support of this notion, earlier serological studies have demonstrated the detection of circulating neutralizing antibody to JCV in approximately 50% of the population under the age of 20 reaching levels of greater than 70% of the adult population Walker and Padgett, 1983) . More recent reports have shown the detection of JCV by PCR in the urine of nearly 50% of healthy individuals under the age of 30, while the percentage of individuals shedding JCV into their urine steadily increases with age (Kitamura et al., 1994) . Owing to the prevalence of infection and the observation that JCV may be detected in tonsilar stromal cells (Monaco et al., 1998) , viral transmission via the respiratory route has been hypothesized. However, recent evidence detecting viral DNA in the gastrointestinal tract and the presence of viral genomic sequences in raw urban sewage suggest the possible fecal/oral transmission of JCV and also emphasize the relative stability of viral particles (Ricciardiello et al., 2000; Bofill-Mas et al., 2001) .
Insight regarding potential sites of latency in the body may come from infection experiments performed in cell cultures. Standard methods of culturing brain-derived isolates of JCV have utilized primary human fetal glial cells, which are prepared from human fetal brain tissue and include populations of astrocytic, oligodendrocytic, as well as other cell types. Owing to the difficulty in obtaining human fetal tissue, and the inherent lack of uniformity of primary cultures, initial cell culture studies of JCV had been hampered by the lack of a stable cell line permissive for productive infection with JCV. However, several strains of JCV have been successfully propagated in a number of primary cultures and established cell lines ( Table 1 ). As might be anticipated, the virus is able to grow in the astrocytic cell lines, SVG and POJ, which were generated via transformation of primary fetal glial cells with replication-defective SV40 and JC virus, respectively (Major et al., 1985; Mandl et al., 1987) . Also, primary cultures of Schwann cells, the myelin-producing cells in the peripheral nervous system, are reported to be capable of supporting JCV replication (Assouline and Major, 1991) . Of interest, in more recent studies, several neuroblastoma cell lines have been shown to support productive JCV infection (Akatani et al., 1994; Shinohara et al., 1997) . The virus has also been found to infect hematopoietic progenitor cells, B lymphocytes, and tonsilar stromal cells, although with much less efficiency (Monaco et al., 1998) . With few exceptions, the cell lines capable of supporting productive JC viral infection are of human origin. The ability of JCV to infect human cells may be restricted at the level of viral DNA replication via the compatibility of Tantigen with the host synthesis machinery. In support of this notion, domain swapping of the carboxy termini of Transformed with origin-defective SV40, expresses SV40 T-antigen PHFG, primary human fetal glial; AHB, adult human brain; PHFS, primary human fetal Schwann cells.
JCV and SV40 T-antigen, the region responsible for host-range specificity, enables JCV DNA replication in non-human primate cells (Lynch et al., 1994) . Of note, the Archetypal strain of JCV, which is derived from the kidney, can be propagated in the SV40-transformed cell line, COS-7, which was derived from African Green monkey kidney tissue. One may hypothesize that the presence of high levels of SV40 T-antigen may enable JCV to overcome the species-specific blockage and permit replication of the viral DNA. However, using chimeric regulatory regions in which SV40 enhancer sequences are inserted into the JCV promoter may extend the host range of JCV to primate cells . Thus, it is likely that the host range and cell-type specificity of JCV may be determined by the viral regulatory region, in addition to T-antigen coding sequences.
Laboratory animal studies
Earlier efforts in animals focused on the development of a suitable in vivo model of PML. Toward this end, JCV strains isolated from the brains of individuals with PML were inoculated into newborn Syrian golden hamsters by various routes including intracerebral, intraocular, and intraperitoneal. Significant numbers of the animals developed neuronal and glial-origin tumors, most frequently medulloblastoma, peripheral neuroblastoma, astrocytoma, and primitive neuroectodermal tumors Zu Rhein, 1983) . Detailed analyses of less frequent tumors arising in hamsters highlight a broad collection of neoplasias including ependymoma, pineocytoma, pituitary carcinoma, retinoblastoma, choroid plexus papilloma, hemangiosarcoma, and malignant schwannoma (Zu Rhein, 1983; Brun and Jonsson, 1984; Nagashima et al., 1984) . Similar studies performed using newborn Sprague-Dawley rats with the Tokyo-1 strain of the virus resulted in the induction of primitive neuroectodermal tumors (Ohsumi et al., 1986) . When examined by immunohistochemical analysis, the tumor tissues showed the expression of the viral T-antigen in the nucleus of the tumor cells. However, attempts to detect signs of viral replication including the expression of the viral late capsid proteins by immunohistochemistry or virion formation by electron microscopy were unsuccessful. No signs of myelin pathology in any of the rodent models described above have been reported in the literature.
Additional experiments were then designed to determine the effect of age at the time of viral inoculation. Golden Syrian hamsters inoculated intracerebrally with virus shortly after birth were found to develop tumors at much higher frequencies than animals inoculated at 2 weeks of age (Matsuda et al., 1987) . Furthermore, animals inoculated at birth had a much greater likelihood for developing cerebellar medulloblastomas than animals inoculated later in age, who more frequently developed glial-origin tumors in the cortex. Several studies have reported the appearance of microscopic tumors in the internal granular layer of the cerebellum of inoculated newborn hamsters and have suggested that cells of the external granular layer, which are actively replicating and migrating inward during early development, may be vulnerable to initial infection with JCV (Zu Rhein and Varakis, 1979; Nagashima et al., 1984; Matsuda et al., 1987) . It is interesting to note that the cells of the external granular layer originate in the neural crest and are believed to give rise to medulloblastoma in humans. In fact, the majority of the neoplasias described in the hamster and rat models are tumors arising from cells of the neural crest, which include medulloblastoma, primitive neuroectodermal tumors, glial-origin tumors, as well as others.
A number of experiments using New World primates, owl and squirrel monkeys, inoculated with purified JCV have also been detailed in the literature. The majority of the monkeys were inoculated intracerebrally as adults, and a small subset received immunosuppressive drugs prior to and following inoculation to aid in tumor inducement (London et al., 1978) . Several of the infected animals, with and without immunosuppression, developed glial neoplasias in adulthood, including glioblastoma multiforme and astrocytoma. With one exception, no evidence of viral replication was observed, although the expression of the early gene, T-antigen, was detected by immunohistochemistry or by Western blot analysis. Cells cultured from an astrocytoma arising in one owl monkey inoculated with JCV were found to produce spontaneously infectious JC viral particles, although some rearrangement of the viral regulatory region may have occurred (Major et al., 1987) . In all, JCV remains the only human virus reported to induce solid tumors in non-human primates.
Transgenic mouse models
Through the use of transgenic mice containing the gene for JCV T-antigen under the control of the viral early promoter, the role of T-antigen can be studied in the absence of sequences encoding the capsid proteins. A number of independent lines of transgenic mice have been generated to date, which exhibit distinct phenotypes, as summarized in Table 2 . Occasionally, founder animals exhibiting signs of poor motor coordination and shaking consistent with the behavior seen in spontaneous mutant models of demyelination have been observed in mice generated with the Mad-4 strain of the virus, suggesting alterations in myelin sheath formation. Indeed, electron microscopy revealed a lack of myelin sheath surrounding axons of the spinal cord and the presence of noncompacted myelin in two independent lines of mice (Small et al., 1986a, b) . Subsequent molecular studies have suggested that JCV T-antigen may directly affect myelin gene expression at the transcriptional level (Haas et al., 1994; Devireddy et al., 1996) , while the possibility of an indirect effect from neighboring T-antigen expressing astrocytes has been suggested from the analysis of mouse polyoma virus T-antigen transgenic mice with dysmyelination (Baron- Van Evercooren et al., 1992) . The dysmyelinating phenotype has been observed in several founder animals, but its severity has prevented their successful breeding.
In addition to deficits in myelin sheath formation, the same construct has been found to induce peripheral neuroblastomas and adrenal neuroblastomas on two different genetic backgrounds. Using the Archetype, or kidney-derived isolate of JCV as the source of the transgene, mice developed cerebellar tumors resembling human medulloblastoma. Similar to peripheral neuroblastomas, these very cellular tumors have a high mitotic index, contain scant cytoplasm, and exhibit positivity for the neuronal marker synaptophysin (Figure 2 , panels a and b). Approximately 80% of the animals develop medulloblastomas between 9 and 12 months of age. The tumors impede motor coordination and balance usually resulting in hemiparesis as the overt phenotype. Immunohistochemical studies have demonstrated that the majority of tumor cells contain high levels of Tantigen in the nucleus (Figure 2, panel c) . Western blotting and immunoprecipitation/Western blot analysis have revealed high levels of T-antigen protein in the tumor tissue in association with the tumor suppressor proteins, p53 and pRb (Krynska et al., 1999a, b) . Cells cultured from the tumor tissue have been separated into clonal populations of T-antigen-positive and T-antigennegative cells with only T-antigen-positive cell lines showing the ability to grown subcutaneously in Nude mice (Krynska et al., 2000) . Molecular analysis revealed that the T-antigen-negative cell lines harbor a point mutation affecting an intron-exon junction, which results in the expression of a smaller in-frame p53 mRNA species lacking exon 4 (Krynska et al., 2000) . Interestingly, this region of p53 is located in close proximity to the T-antigen binding site, and therefore suggests that tumor cells may require the presence of T-antigen for inactivation of p53, while cells in which mutant p53 variants are expressed may no longer require T-antigen expression.
In another series of transgenic mouse studies using the Mad-4 JCV isolate as the source of the T-antigen transgene in C57BL/6 mice, two different tumor phenotypes were observed to arise in the same line of mice. The appearance of pituitary adenomas in the transgenic mice appeared at high frequency with a penetrance of approximately 75% in mice greater than 1 year of age . Large hemorrhagic intracranial masses were frequently observed, which microscopically exhibited a high degree of pleomorphism as well as a subset of prolactin-producing cells indicating the pituitary gland as the origin of the tumors (Figure 2 , Panels d and e, respectively). These tumors had strong nuclear positivity for T-antigen in approximately 50% of the tumor cells (panel f). This same line of JCV T-antigen transgenic mice occasionally developed large, wellcircumscribed masses in the scapular region or along the extremities. Hematoxylin and eosin staining revealed interdigitating spindle cells and expression of the neuronal marker protein, S-100 (Figure 2 , Panels g and h, respectively), consistent with malignant peripheral nerve sheath tumors (mpnst) (Gordon et al., unpublished observations). Interestingly, the incidence of pituitary tumors and mpnst mimics that observed in the human population in that pituitary tumors have a relatively high incidence as they account for 8-10% of all intracranial neoplasms, while mpnst are fairly uncommon (Leon et al., 1994; Woodruff et al., 2000) . Observations similar to those made in the mouse medulloblastoma tumors, namely the expression of T-antigen in the tumor tissue and its association with p53 and pRb, have been made in the pituitary tumors and mpnst as well. Consistent in all the murine tumors were a majority of cells exhibiting intense nuclear staining for T-antigen and a subset of cells which appear negative for T-antigen by immunohistochemistry (Figure 2 , panels c, f, and i).
Association of JCV with human brain tumors
While previous case reports in the literature noted the association of CNS tumors in individuals with PML, most of these early cases appear circumstantial. Initial descriptions of PML by EP Richardson reported the disorder as a 'heretofore unrecognized complication of lymphatic leukemia or Hodgkin's disease', and the white matter lesions were generally discovered as incidental findings upon autopsy (Richardson, 1961) . In the majority of the cases of concomitant PML and CNS tumors, the patients developed an immunosuppressive disease such as CNS lymphoma or were renal transplant recipients receiving immunosuppressive drugs to control graft rejection. Two cases of glial tumors with concomitant PML have been documented, one describing an individual with an 'immunodeficiency syndrome', and the other with no apparent underlying immunosuppressive disease (Castaigne et al., 1974; Sima et al., 1983) . However, in these cases, as well as the CNS lymphomas described above, viral replication was noted only in the adjacent PML lesions, but not within the tumor itself. In more recent years, mounting evidence has suggested that JCV may be associated with human neoplasms in the absence of immunosuppression or PML. Through the use of sensitive molecular techniques and the availability of more reliable immunochemical reagents, JC viral genomic sequences and expression of T-antigen have been observed in a variety of human tumor cell types. Rencic et al. (1996) reported the first case in which viral DNA and expression of JCV T-antigen were detected in the oligodendroglial portion of an oligoastrocytoma by PCR/Southern blot hybridization, immunohistochemistry, and Western blotting. Subsequent analyses of oligodendrogliomas have revealed viral DNA in 20-75% and T-antigen expression in up to 50% of tumors, as detailed in Table 3 In addition to tumors of oligodendrocytes, the presence of JCV has been investigated in a broad range of glial-origin tumors including astrocytomas, anaplastic astrocytic, anaplastic oligodendroglial, as well as glioblastomas and ependymomas. As shown in Table 3 , JCV DNA has been detected in nearly every known type of malignant and nonmalignant tumor which arise from cells of the CNS. It is of interest that low-grade tumors such as oligodendrogliomas are as likely to contain JCV DNA or express JCV T-antigen as a WHO Grade IV tumor such as a glioblastoma multiforme (Figure 3 , Panels d, e, f). As such, it does not seem that the detection of JCV can be correlated with the aggressiveness or malignancy of the tumor, nor the type of glial tumor. It should be noted that viral DNA may be detected more frequently than JCV T-antigen expression in the tumor tissues studied. Thus, the viral genome, while it may be present, may not be expressed at levels detectable by immunohistochemical analysis. Alternatively, the viral early coding region simply may not be expressed.
Taking cues from the tropism of JCV in transgenic mice, a series of human medulloblastomas were evaluated for the presence of JCV. Medulloblastomas are the most common malignant brain tumor in children with nearly 70% appearing in children under the age of 16 and rarely occurring in individuals over 50 (Molenaar and Trojanowski, 1994) . While a small percentage are related to genetically defined heritable syndromes associated with neoplasias, the majority are sporadic and of unknown etiology. A number of mutant genes have been detected in medulloblastoma, including the human homologue of patched (PTCH) and b-catenin of the Wnt signaling pathway. Infrequently, mutations in the p53 gene are found. In two separate studies of 43 well-characterized medulloblastomas, nearly 77% were shown to contain viral DNA corresponding to the N-terminal region of JCV T-antigen, while 36% of the tumors analysed by immunohistochemistry showed regions of the tumor with nuclear positivity for T-antigen (Figure 3, Panels a, b, c) . In one study, the expression of the JCV late protein, Agnoprotein, was detected in 69% of tumor samples (Del Valle et al., 2002a) . Agno is an auxiliary protein whose function remains unclear; however, recently it has been shown to be expressed early in viral infection and can interact with T-antigen to regulate viral transcription and replication (Safak et al., 2001) . Interestingly, in human tumor samples, Agnoprotein has been found to be expressed in the cytoplasm of tumor cells and its expression does not appear to correlate with the expression of T-antigen. Most recently, a role for Agnoprotein in dysregulation of the cell cycle by binding to p53 and upregulating transcription of the p21/WAF-1 promoter has been described (Darbinyan et al., 2002) . However, further experiments are needed to determine what functional role, if any, that Agnoprotein may play in human tumorigenesis.
Association of JCV with non-neural human tumors
Owing to the tropism of the virus to non-CNS origin tissues such as kidney, and the potential for normal healthy individuals to excrete JCV in their urine, surveys of waste water were analysed for JCV and several studies have reported the detection of JCV viral particles in raw sewage in a number of urban areas (Kitamura et al., 1994; Bofill-Mas et al., 2001) . In light of the potential fecal-oral transmission of JCV, researchers have determined that JCV DNA is present in the upper and lower human gastrointestinal tract (Riccardiello et al., 2000 (Riccardiello et al., , 2001 . To follow-up on these observations, a series of adenocarcinomas of the colon were surveyed by PCR/Southern blot hybridization and immunohistochemistry for the presence of JCV. In one study, 83% of 29 tumor samples analysed were found to contain viral DNA sequences (Laghi et al., 1999) , while a second study detected viral DNA in 81% of 27 samples and nuclear T-antigen by immunohistochemistry in 63% of the samples (Figure 3 , Panels g,h,i) (Enam et al., 2002) . In addition, approximately 44% of the colorectal tumors also contained evidence of JCV Agnoprotein as well (Enam et al., 2002) . It is interesting to note that the colon tumors contain JCV DNA and express the viral T-antigen protein at very high percentages, at similar percentages as seen in the CNS-origin tumors. The prevalence of JCV sequences and T-antigen in these tumors, along with the human glial and medulloblastomas origin tumors described above suggests that these cell types are permissive for the expression of the JCV early promoter, which may lead to the accumulation of T-antigen and potential cellular transformation. This evidence, taken together with other potential sites of latency in humans, including B cells and kidney epithelium, suggest areas of further study to investigate the presence of JCV in normal and tumor tissues of non-CNS origin. 
Mechanisms of T-antigen-mediated transformation
A wealth of information concerning the potential mechanisms by which T-antigen may lead to cellular transformation has been obtained through in vitro analysis as well as through the study of tissues from T-antigen-induced tumors in experimental animal models. As described above, the dysregulation of cell-cycle pathways through physical interaction with the tumor suppressor proteins, p53 and pRb, is a common theme in the majority of the animal models and has been well described in cell culture systems. However, there are likely additional levels at which T-antigen may interfere with cellular functions. Interestingly, in several of the tumor tissues, the expression of p21/WAF-1 was found to be high in tumor cells where p53 is sequestered by T-antigen, indicating potential p53-independent activation of p21/WAF-1 .
Additional mechanisms by which T-antigen may exert control over cell proliferation have been observed through studying signaling pathways in mouse medulloblastoma cells. As a subset of human medulloblastomas have shown deregulation of the Wnt signaling pathway, T-antigen-positive and -negative mouse medulloblastoma cell lines were evaluated for their levels of b-catenin, its cellular partner, LEF-1, and their activity on their downstream target, c-myc. Of interest, enhanced levels of b-catenin and LEF-1 and a subsequent increase in c-myc levels were observed in T-antigen-positive cells compared with T-antigen-negative cells (Gan et al., 2001) . In another recent line of study, a role for the insulin-like growth factor I receptor (IGF-IR) signaling system has been observed in the T-antigen-positive medulloblastoma cell lines. More specifically, physical interaction of T-antigen with the insulin receptor substrate 1 (IRS-1), the major signaling molecule of IGF-IR, and its nuclear localization in human medulloblastoma biopsies suggest an additional signaling pathway that may be deregulated by JCV T-antigen (Del Valle et al., 2002d) .
In addition to its effect on the cell cycle, JCV T-antigen has been shown to possess mutagenic activity and may contribute to chromosomal instability observed in B lymphocytes (Theile and Grabowski, 1990 ; Tumors were further characterized by immunohistochemistry for their expression of cell-type-specific markers confirming the tissue of origin including the neuronal marker, synaptophysin, expressed by medulloblastomas (panel b), the glial-specific marker, GFAP (panel e), and the epithelial marker cytokeratin for adenocarcinomas (panel h). Immunohistochemical staining for JCV T-antigen shows positive staining in the nuclei of tumor cells in all three tumor types (panels c, f, and i, respectively). (panels a, d, and G: hematoxylin and eosin staining; panels b, c, e, f, h, and i: hematoxylin counterstain; All panels: original magnification Â 400) Lazutka et al., 1996; Neel et al., 1996) . In further evidence of the ability of T-antigen to induce alterations at the chromosome level, morphological changes such as multinucleation, high nuclear pleomorphism, aneuploidy, and polyploidy have been observed in T-antigeninduced transgenic mouse tumors and cell cultures derived from those tumors (Krynska et al., 2000; Gordon et al., unpublished observations) . Once dysregulation of one or more cellular pathways or induction of chromosomal instability occurs, shifts in cell-cycle profiles or genetic mutations may render T-antigen expression unnecessary. Such a 'hit-and-run' or a multistep transformation strategy has been suggested for cancers such as colorectal carcinoma. The observed loss of T-antigen expression in subpopulations of neural-origin tumor cells suggests that T-antigen may function at an earlier rather than later step in tumorigenesis.
Discussion
It should be noted that transcriptional activation of the JCV early promoter in a given cell type is necessary for T-antigen expression. When JCV early gene expression is followed by viral DNA replication and late gene expression, a productive infection results. As is the case with PML, JCV-infected oligodendrocytes are permissive for viral lytic infection and are destroyed in the process, leading to demyelination. However, one can envision a scenario in which an infected cell may be permissive for early gene expression, although not able to support viral replication or late gene expression. In this setting, the expression of T-antigen may lead to inactivation of tumor suppressors, dysregulation of signaling pathways, or DNA instability, which could contribute to transformation and subsequent tumorigenesis. Factors contributing to the permissiveness of a given cell type may lie in its tissue of origin, point of development, or state of differentiation. For example, perhaps it is the mature oligodendrocyte that can fully support a viral lytic infection while an undifferentiated oligodendrocyte may only allow T-antigen expression, leading to the development of an oligodendroglioma. Given the well-established tissue tropism of JCV toward neural-origin cells and the predilection in animal models for induction of tumors of neural crest origin, one may anticipate the detection of JCV in neuronal and glialorigin tumors. However, more recent evidence demonstrating the presence of the virus in sewage and in The growing body of literature detecting JCV, as well as SV40 and BKV sequences, in normal and pathologic human tissues raises several important issues, which must be carefully considered. Firstly, the presence of viral genomic DNA in itself does not establish causation. It is necessary to show the expression of viral genes in order suggest their participation in aberrant cellular proliferation. However, as T-antigen expression may not be required for maintenance of a transformed state, it may be difficult to establish whether or not polyomaviral DNA present in a tumor did in fact result in the production of viral proteins. In any case, T-antigen, when expressed, has well-established oncogenic properties and is capable of targeting a number of key cellular regulatory pathways and it is likely that additional cellular pathways affected by T-antigen expression will be uncovered by future in vitro and in vivo studies. As such, mechanisms of T-antigen-mediated transformation can be studied in vitro and through the use of laboratory animal models to provide better understanding of cellular regulatory pathways involved in tumorigenesis. Such studies may lead to the identification of therapeutic targets in JCV-transformed cells, potentially even the targeting of T-antigen itself.
